1. Home
  2. CASS vs ERAS Comparison

CASS vs ERAS Comparison

Compare CASS & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cass Information Systems Inc

CASS

Cass Information Systems Inc

HOLD

Current Price

$42.94

Market Cap

503.5M

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$3.28

Market Cap

439.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CASS
ERAS
Founded
1906
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
503.5M
439.7M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
CASS
ERAS
Price
$42.94
$3.28
Analyst Decision
Buy
Buy
Analyst Count
2
6
Target Price
$45.50
$3.50
AVG Volume (30 Days)
95.6K
1.9M
Earning Date
01-22-2026
11-12-2025
Dividend Yield
2.96%
N/A
EPS Growth
37.29
N/A
EPS
2.31
N/A
Revenue
$222,318,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.33
N/A
P/E Ratio
$21.30
N/A
Revenue Growth
7.50
N/A
52 Week Low
$36.08
$1.01
52 Week High
$47.00
$3.38

Technical Indicators

Market Signals
Indicator
CASS
ERAS
Relative Strength Index (RSI) 65.36 65.86
Support Level $40.52 $2.81
Resistance Level $43.68 $3.38
Average True Range (ATR) 1.01 0.24
MACD 0.17 0.03
Stochastic Oscillator 84.70 87.23

Price Performance

Historical Comparison
CASS
ERAS

About CASS Cass Information Systems Inc

Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. It operates in two segments: Information Services and Banking Services. The firm generates maximum revenue from the Information Services segment, which provides transportation, energy, telecommunication, and environmental invoice processing and payment services to large corporations.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Share on Social Networks: